Cargando…
Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995–2021
BACKGROUND: Sacubitril/valsartan has been approved for the treatment of heart failure (HF) patients with reduced ejection fraction; since then, it gradually became a new star drug in the therapy of HF. Nevertheless, the effectiveness of sacubitril/valsartan remains under investigation. Thus far, onl...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351920/ https://www.ncbi.nlm.nih.gov/pubmed/35945796 http://dx.doi.org/10.1097/MD.0000000000029398 |
_version_ | 1784762537228632064 |
---|---|
author | Lai, Ping Xue, Jin-Hua Xie, Mu-Jin Ye, Jin-Hua Tian, Ke-Jun Ling, Jia-Yuan Zhong, Wen-Ting Chen, Dong Zhong, Yi-Ming Liao, Yong-Ling |
author_facet | Lai, Ping Xue, Jin-Hua Xie, Mu-Jin Ye, Jin-Hua Tian, Ke-Jun Ling, Jia-Yuan Zhong, Wen-Ting Chen, Dong Zhong, Yi-Ming Liao, Yong-Ling |
author_sort | Lai, Ping |
collection | PubMed |
description | BACKGROUND: Sacubitril/valsartan has been approved for the treatment of heart failure (HF) patients with reduced ejection fraction; since then, it gradually became a new star drug in the therapy of HF. Nevertheless, the effectiveness of sacubitril/valsartan remains under investigation. Thus far, only a few bibliometric studies have systematically analyzed the application of sacubitril/valsartan. METHODS: Publications on sacubitril/valsartan were retrieved from the Web of Science Core Collection on April 29, 2021. Data were analyzed using Microsoft Excel 2019 (Redmond, WA), VOS viewer (Redmond, WA), and Cite Space V (Drexel University, Philadelphia, PA). RESULTS: A total of 1309 publications on sacubitril/valsartan published from 1995 to 2021 were retrieved. The number of publications regarding sacubitril/valsartan increased sharply in the last 6 years (2015–2021), and American scholars authored >40% of those publications. Most were published in the European Journal of Heart Failure, the United States was the bellwether with a solid academic reputation in this area. Solomon published the highest number of related articles and was the most frequently cited author. “Heart failure” was the leading research hotspot. The keywords, “inflammation,” “fibrosis,” and “oxidative stress” appeared most recently as research fronts. CONCLUSIONS: Research attention should be focused on clinical trial outcomes. Considering its effectiveness in HF, the mechanisms and further applications of sacubitril/valsartan may become research hotspots in the future and should be closely examined. |
format | Online Article Text |
id | pubmed-9351920 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-93519202022-08-05 Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995–2021 Lai, Ping Xue, Jin-Hua Xie, Mu-Jin Ye, Jin-Hua Tian, Ke-Jun Ling, Jia-Yuan Zhong, Wen-Ting Chen, Dong Zhong, Yi-Ming Liao, Yong-Ling Medicine (Baltimore) Research Article BACKGROUND: Sacubitril/valsartan has been approved for the treatment of heart failure (HF) patients with reduced ejection fraction; since then, it gradually became a new star drug in the therapy of HF. Nevertheless, the effectiveness of sacubitril/valsartan remains under investigation. Thus far, only a few bibliometric studies have systematically analyzed the application of sacubitril/valsartan. METHODS: Publications on sacubitril/valsartan were retrieved from the Web of Science Core Collection on April 29, 2021. Data were analyzed using Microsoft Excel 2019 (Redmond, WA), VOS viewer (Redmond, WA), and Cite Space V (Drexel University, Philadelphia, PA). RESULTS: A total of 1309 publications on sacubitril/valsartan published from 1995 to 2021 were retrieved. The number of publications regarding sacubitril/valsartan increased sharply in the last 6 years (2015–2021), and American scholars authored >40% of those publications. Most were published in the European Journal of Heart Failure, the United States was the bellwether with a solid academic reputation in this area. Solomon published the highest number of related articles and was the most frequently cited author. “Heart failure” was the leading research hotspot. The keywords, “inflammation,” “fibrosis,” and “oxidative stress” appeared most recently as research fronts. CONCLUSIONS: Research attention should be focused on clinical trial outcomes. Considering its effectiveness in HF, the mechanisms and further applications of sacubitril/valsartan may become research hotspots in the future and should be closely examined. Lippincott Williams & Wilkins 2022-08-05 /pmc/articles/PMC9351920/ /pubmed/35945796 http://dx.doi.org/10.1097/MD.0000000000029398 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | Research Article Lai, Ping Xue, Jin-Hua Xie, Mu-Jin Ye, Jin-Hua Tian, Ke-Jun Ling, Jia-Yuan Zhong, Wen-Ting Chen, Dong Zhong, Yi-Ming Liao, Yong-Ling Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995–2021 |
title | Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995–2021 |
title_full | Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995–2021 |
title_fullStr | Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995–2021 |
title_full_unstemmed | Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995–2021 |
title_short | Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995–2021 |
title_sort | emerging trends in sacubitril/valsartan research: a bibliometric analysis of the years 1995–2021 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351920/ https://www.ncbi.nlm.nih.gov/pubmed/35945796 http://dx.doi.org/10.1097/MD.0000000000029398 |
work_keys_str_mv | AT laiping emergingtrendsinsacubitrilvalsartanresearchabibliometricanalysisoftheyears19952021 AT xuejinhua emergingtrendsinsacubitrilvalsartanresearchabibliometricanalysisoftheyears19952021 AT xiemujin emergingtrendsinsacubitrilvalsartanresearchabibliometricanalysisoftheyears19952021 AT yejinhua emergingtrendsinsacubitrilvalsartanresearchabibliometricanalysisoftheyears19952021 AT tiankejun emergingtrendsinsacubitrilvalsartanresearchabibliometricanalysisoftheyears19952021 AT lingjiayuan emergingtrendsinsacubitrilvalsartanresearchabibliometricanalysisoftheyears19952021 AT zhongwenting emergingtrendsinsacubitrilvalsartanresearchabibliometricanalysisoftheyears19952021 AT chendong emergingtrendsinsacubitrilvalsartanresearchabibliometricanalysisoftheyears19952021 AT zhongyiming emergingtrendsinsacubitrilvalsartanresearchabibliometricanalysisoftheyears19952021 AT liaoyongling emergingtrendsinsacubitrilvalsartanresearchabibliometricanalysisoftheyears19952021 |